IY
IYXI.US Inyx Inc
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2006.
Is IYXI.US undervalued?
Graham numberThe Graham number of Inyx Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Inyx Inc fundamental analysis
No fundamental analysis for Inyx Inc yet.
Inyx Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Inyx Inc
Inyx, Inc., through its wholly-owned subsidiaries, operates as a specialty pharmaceutical company in the United States, Canada, and Europe. It develops and manufactures prescription and over-the-counter pharmaceutical products. The company manufactures hydrocarbon aerosols, a delivery system for dermatological and topical drug applications; metered dose inhalers that are used for respiratory conditions; dry powdered inhalers used for respiratory ailments; metered dose nasal …
Full company profileInyx Inc financial statements
2006 annualized: Fiscal year 2006 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2006, the balance sheet is the latest quarter. Figures change when the annual report is published.
Inyx Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2002 | 2003 | 2004 | 2005 | 2006 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 21.2M | 15.5M | 15.7M | 49.6M | 79.4M |
| Gross Profit | 3.86M | 2.99M | 1.38M | 14.7M | 31.1M |
| Operating Income | -3.89M | -8.55M | -12.2M | -18.0M | -14.3M |
| Net Income | -31.0M | -14.3M | -16.9M | -31.0M | -29.6M |
| Balance Sheet | |||||
| Total Assets | - | 15.5M | 14.8M | 92.2M | 114M |
| Total Liabilities | - | 13.6M | 20.6M | 123M | 153M |
| Shareholders' Equity | - | 1.84M | -5.87M | -30.4M | -38.9M |
| Cash & Short-term Investments | - | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow | |||||
| Operating Cash Flow | 3.24M | -6.04M | -9.02M | -17.9M | -16.2M |
| Capital Expenditure | 1.97M | 412K | 1.64M | 2.19M | 7.07M |
| Ratios | |||||
| ROE | - | -776.8% | - | - | - |
| ROA | - | -92.3% | -114.8% | -33.6% | -25.8% |
| Net Profit Margin | -146.3% | -92.3% | -107.9% | -62.6% | -37.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Inyx Inc dividends
Inyx Inc has not paid dividends in the last 4 fiscal years.
Last stock split: 5:1 on Mar 5, 2003.
Who owns Inyx Inc
- Insiders 0.00%
- Institutions 0.32%
- Public & others 99.68%
Inyx Inc company profile
- Company name
- Inyx Inc
- Ticker
- IYXI.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 572
- Fiscal year end
- December
- Address
- 825 Third Avenue, New York, NY, United States, 10022
- Phone
- 212-838-1111
- Website
- -
About Inyx Inc
Inyx, Inc., through its wholly-owned subsidiaries, operates as a specialty pharmaceutical company in the United States, Canada, and Europe. It develops and manufactures prescription and over-the-counter pharmaceutical products. The company manufactures hydrocarbon aerosols, a delivery system for dermatological and topical drug applications; metered dose inhalers that are used for respiratory conditions; dry powdered inhalers used for respiratory ailments; metered dose nasal and throat pumps, and sprays; and sterile salines and injectables. It focuses on research and development activities on inhalation-therapy drug delivery devices and inhalation methods, and generic prescription, and over-the-counter aerosol pharmaceutical products for respiratory, allergy, dermatological, and topical and cardiovascular applications. The company's proprietary products under development include generic versions of nonchlorofluorocarbon or hydrofluoroalkane single molecule and combination drug respiratory inhalants, nonCFC propelled oral sprays for cardiovascular ailments, wound irrigation, and cleansing sprays that utilize novel barrier technologies, and anti-inflammatory nasal pumps. It also provides specialty pharmaceutical development and manufacturing consulting services to the international healthcare market. The company was incorporated in 2000 and is based in New York, New York.
Inyx Inc management
5- Mr. Steven HandleyPresident & Director · born 1964
- Mr. Jay M. GreenExecutive VP, Director of Corporate Development & Director · born 1950
- Ms. Carole RichardsonCorporate Administration Manager of Inyx Pharma Ltd.
- Mr. William KellyVice President of Corporate Communications & Investor Relations
- Mr. Stephen BeckmanVice President of Sales & Marketing and Commercial Development · born 1967